|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 935.3 INR | +0.19% |
|
-0.27% | +35.59% |
| Apr. 24 | Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection | MT |
| Apr. 23 | China Medical System's Anti-Anaemia NDA Accepted in China | MT |
Indian pharmaceutical company Zydus said on Wednesday it has started human studies for its potential COVID-19 vaccine, as coronavirus infections continue to surge in the world's third worst-hit nation.
ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said https://www.bseindia.com/xml-data/corpfiling/AttachLive/055682c2-b6b3-43b0-aff5-2ac50fe9b087.pdf.
In the human trials, Zydus will enrol over 1,000 subjects across multiple clinical study sites in India.
(Reporting by Chandini Monnappa in Bengaluru, Editing by Sherry Jacob-Phillips)
| 1st Jan change | Capi. | |
|---|---|---|
| +35.59% | 11.27B | |
| +20.18% | 42.78B | |
| +18.59% | 22.25B | |
| +13.97% | 14.39B | |
| +12.25% | 13.55B | |
| -9.80% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.29% | 5.01B | |
| -8.24% | 4.51B |
ZYDUS LIFESCIENCES LIMITED 
